Skip to main content
OpenTrials
Completed

NCT Number: NCT04144738

Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C"

The primary objective of this study is to assess the sensitivity for colorectal cancer (CRC) and specificity of the mt-sDNA 2.0 test.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Parkway Medical Center, Birmingham, Alabama, United States

Loading trial locations.

About this study

Subjects 40 years of age and older scheduled for a screening colonoscopy will be enrolled. Subject will complete the mt-sDNA 2.0 test and the commercially available FIT, followed by completion of a screening colonoscopy. The results of the mt-sDNA screening test and FIT will not be provided to investigators for clinical management of the study subject. Personnel performing the colonoscopy and producing the resulting report and personnel performing histopathologial review of reports or tissue (if applicable) will remain blinded to the results of the mt-sDNA 2.0 screening test results.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects must meet the following criteria to be eligible for the study:

  • Subject is ≥ 40 years of age at the time of enrollment.
  • Subject presents for a screening colonoscopy per standard of care.
  • Subject has no symptoms or signs that require immediate, or near term, referral for diagnostic or therapeutic colonoscopy.
  • Subject is able and willing to sign informed consent

Exclusion criteria

  • Subject has a history of CRC or advanced precancerous lesions.
  • Subject has a diagnosis or medical / family history of any of the following conditions, including:
  • Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP and Gardner's syndrome),
  • Hereditary non-polyposis CRC syndrome (also referred to as "HNPCC" or "Lynch Syndrome"),
  • Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis, or Familial Hyperplastic Polyposis.
  • Subject has a diagnosis or personal history of inflammatory bowel disease (IBD) including chronic ulcerative colitis and/or Crohn's disease.
  • Subject has a diagnosis of Cronkhite-Canada Syndrome.
  • Subject has had a positive Cologuard within the previous 2 years, or fecal occult blood test or FIT within the previous 6 months.
  • Subject has undergone a colonoscopy within the previous 9 years with the exception of a failed colonoscopy due to poor bowel preparation. Failed colonoscopy must have been within the past year and without therapeutic intervention.
  • Subject has had overt rectal bleeding within the previous 30 days.
  • Subject has any condition that in the opinion of the Investigator should preclude participation in the study.

Treatment and study plan

mt-sDNA 2.0 screening test

Diagnostic Test

Stool samples will be collected by the subject for the mt-sDNA screening test.

FIT test

Diagnostic Test

Stool samples will be collected by the subject for the FIT test.

colonoscopy

Procedure

Subjects will undergo a screening colonoscopy.

Primary outcomes

  1. Sensitivity for CRC with the mt-sDNA 2.0 test

    Time frame: Through study completion, an average of 180 days

  2. Specificity with the mt-sDNA 2.0 test

    Time frame: Through study completion, an average of 180 days

Secondary outcomes

  1. Sensitivity for advanced precancerous lesions

    Time frame: Through study completion, an average of 180 days

  2. Sensitivity for CRC compared to a commercially available fecal immunochemical test (FIT)

    Time frame: Through study completion, an average of 180 days

  3. Sensitivity for advanced precancerous lesions compared to commercially available fecal immunochemical test (FIT).

    Time frame: Through study completion, an average of 180 days

  4. Specificity for no colorectal neoplastic findings

    Time frame: Through study completion, an average of 180 days

Sponsors and collaborators

Lead sponsor

Exact Sciences Corporation

Industry

Registry information

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Oct 30, 2019
Registry last updated
Sep 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.